Antiproliferative and apoptotic activity of a Zn(II) complex against cancer cells, both in vitro and in vivo Authors: Kazi Soha, K M Rashel, Arifur Rahman, Tasnima Kamal, Tumpa Rani Majumder, Saswata Rabi, Pradip Paul, M Matakabbir Hossain, Abdul Auwal, Tasfik Ul Haque Pronoy, Syed Rashel Kabir, M Habibur Rahman, Tapashi G Roy, Nitai Roy, Jahan Ara Khanam, Farhadul Islam Published: 2025 ABSTRACT AbstractBackgroundChemotherapy remains one of the principal treatment strategies in cancer treatment, is widely used but often limited by the development of chemoresistance and adverse side effects.AimsThis study aimed to develop highly effective chemotherapeutic agents with minimal or no adverse effects, specifically focusing on synthesizing a diisothiocyanatozinc(II) complex, [Zn(LCX)(NCS)₂], and evaluating its antineoplastic efficacy and host toxicity.MethodsThe compound’s in vitro anticancer activity was assessed against MCF7 cells using cell growth inhibition, apoptotic morphological observation, and gene expression analysis. In vivo antitumor properties of the compound were assayed in Swiss albino mice bearing EAC cells by monitoring key parameters such as tumor burden, survival rate, tumor cell proliferation, and hematological profiles. Toxicity was evaluated through biochemical, hematological, and histological assessments in mice.ResultsThe compound demonstrated dose-dependent growth (11–85%) inhibition at 20–500 µg/mL doses against MCF7 cells. Compound-treated cells showed apoptotic body formation under fluorescent and phase-contrast microscopes. Notably, mRNA expressions of proapoptotic genes such as p53, Bax, PARP1, Caspase-3, -8, -9, etc., were upregulated while anti-apoptotic genes such as Bcl2 were downregulated in compound-treated cells. Also, the compound showed 83% and 86% inhibition of tumor cell proliferation at doses of 100 and 200 µg/kg/day, respectively, compared to the control group of EAC-bearing mice (p < 0.001). Mice treated with 200 µg/kg/day showed a 60.3% increase in mean survival time compared to untreated controls (p < 0.001). Hematological parameters (RBC, WBC, hemoglobin), which were significantly reduced in EAC-bearing control mice, were restored to near-normal levels in treated mice. Transient alterations in hematological and biochemical parameters (serum glucose, cholesterol, creatinine, SGOT, SGPT) were observed during treatment; however, they normalized post-treatment, indicating minimal host toxicity. The compound also demonstrated a low LC50 value (7.734 µg/mL) in the brine shrimp lethality bioassay, further confirming its pharmacological potential.ConclusionThe [Zn(LCX)(NCS)₂] complex demonstrated potent anticancer activity, followed by induction of apoptosis with minor host toxicity, positioning it as a viable option for advancement as an efficient chemotherapeutic agent. However, more research and clinical studies with animal and human models are needed to further develop the compound as a chemotherapeutic agent.Supplementary InformationThe online version contains supplementary material available at 10.1007/s12672-025-04214-3.Keywords: Angiogenesis, Antineoplastic activity, Antibacterial activity, Apoptosis, EAC cells Introduction Cancer has emerged as the most prevalent pathology worldwide, with a substantial proportion of annually diagnosed oncology patients succumbing to the disease due to inadequate clinical management and limited therapeutic options. As of 2022, global cancer statistics estimate approximately 20 million new cancer cases and 9.7 million cancer-related deaths [1], underscoring the immense and growing burden of this disease. Given the complex and multifaceted nature of cancer, effective treatment requires a diverse arsenal of therapeutic modalities, encompassing surgical intervention, chemotherapy, radiotherapy, stem cell transplantation, targeted molecular therapies, ablative techniques, nanomedicine applications, endogenous antioxidant utilization, radionics, chemodynamic therapy, sonodynamic therapy, and ferroptosis-inducing strategies. These interventions are meticulously tailored to align with specific oncological subtypes and their underlying pathophysiological complexities. Among these strategies, chemotherapy remains a cornerstone of cancer treatment, continuing to play a pivotal role in improving prognosis [2, 3]. In the evolving landscape of anticancer drug development, metal-based compounds have emerged as a promising avenue, gaining significant attention following the discovery of cisplatin, a pioneering metal-based chemotherapeutic agent in the 1990 s [4, 5]. Due to their unique redox properties, versatile coordination behavior, and distinct interactions with biological molecules, metal complexes such as those of copper, nickel, gold, zinc, cobalt, rhodium, platinum, silver, and ruthenium have demonstrated significant anticancer potential [6–9]. Among these, zinc-based complexes, when combined with organic ligands, have shown exceptional cytotoxic activity. For example, Zn-complexes have demonstrated potent anticancer activity by overcoming multidrug resistance mechanisms through reactive oxygen species (ROS)-mediated redox regulation and caspase 3-dependent apoptosis [10–12]. Notably, in vitro cytotoxicity studies of Zn-complexes have exhibited striking activity against human breast (MCF7) cell lines by inducing DNA cleavage properties [13, 14]. Furthermore, Zn-complexes exhibit a dual mode of action, functioning through DNA-damaging mechanisms as well as ROS-mediated pathways, making them particularly attractive as alternative chemotherapeutic agents [13]. Despite these potential properties, zinc-based compounds are relatively underexplored in comparison to other metal-based drugs, including platinum, gold, palladium, ruthenium, and copper complexes. Also, Zn-complexes have a distinct advantage over platinum-based medications in terms of toxicity, fast ligand exchange, Lewis acid activation, and catalytic hydrolytic activity, which includes DNA cleavage and hydrolysis [15, 16]. Therefore, the focus of this study is to explore the cytotoxic and antineoplastic effects of the di-isothiocyanatozinc(II) complex [Zn(LCX)(NCS)₂] against Human breast cancer (MCF7) and Ehrlich Ascites Carcinoma (EAC) cells. In addition, host toxicity of the compound was assessed; thus, this research contributes to the development of a metal-based chemotherapeutic agent that is potentially less toxic but effective by assessing its therapeutic potential in animal models (Fig. 1). Flowchart of the current study. The study synthesized a new Zn(ii) complex, which exhibits potential anticancer activity both in vitro and in vivo through the activation of pro-apoptotic and inactivation of anti-apoptotic genes. In addition, the compound did not show any toxic effects on the tested hosts Materials & methods Chemicals and reagents The study utilized chemicals of analytical grade and reagents sourced from reputable suppliers, including dimethyl sulfoxide (DMSO) from Sigma-Aldrich, St. Louis, MO; Methanol from Duksan, South Korea; Agarose and Tris from MP Biomedicals, LLC, USA, ZnCl₂ (98–100%), KCNS (99%) from Sigma Aldrich, St. Louis, Missouri, USA. RNA extraction kit was purchased from Favorgen, Taiwan, and RT PCR kit from Promega, Madison, Wisconsin. All other chemicals and materials used in this research were of premium quality and were used without any further purification process. Synthesis and characterization of the test compound [Zn(LCX)(NCS)2] Instrumentation Microanalyses (C, H, N analysis) were carried out on a C, H, N analyzer at the Department of Chemistry, Friedrich Schiller University, Jena, Germany. IR spectra were recorded on a Shimadzu IR-20 spectrophotometer as KBr disks at the Department of Chemistry, University of Chittagong, Bangladesh. 1H-NMR spectra were recorded in CDCl3 on a 400 MHz Bruker DPX-400 spectrometer using TMS as internal standard at BCSIR Laboratory, Dhaka, Bangladesh. Conductance measurements were carried out on a Hanna conductivity instrument HI-8820, and Magnetic measurements were performed on a Gouy Balance, which was calibrated using Hg[Co(NCS)4] at the Department of Chemistry, University of Chittagong, Bangladesh. Synthesis The synthesis and characterization of the N-pendant ligand LCX [trans-N4, N11-bis(2-cyanoethyl)2,9-C-meso-2,5,5,7,9,12,12,14-octamethyl-1,4,8,11-tetraazacyclotetradecne] has been reported elsewhere [16, 17]. For the synthesis of the test compound, at first, a precursor dichloridozinc(II) complex of the ligand, [Zn(LCX)Cl2], was prepared, which was subsequently converted into the test compound diisothiocyanatozinc(II) complex, [Zn(LCX)(NCS)2], by an axial ligand exchange reaction according to the following procedure. Dichloridozinc(II) complex [Zn(LCX)Cl2] In a typical procedure, 1.0 mmol (0.42 g) of the N-pendent ligand LCX and 2.0 mmol (0.14 g) of ZnCl2 were dissolved separately in 20.0 mL of hot methanol, and the two solutions were mixed together while hot. Subsequently, the mixed solution was heated on a steam bath till the volume of the solution reduced, and an oily product was obtained. When the oily product was allowed to cool overnight, it turned into a sticky material. This sticky material was treated with methanol and filtered off. The filtrate was dried, and then extracted with chloroform. The chloroform extract was evaporated off and dried in a vacuum desiccator over silica gel. Its melting point (MP) was 130 °C, and it was characterized to be [Zn(LCX)Cl2]. MW: 554.98. Elemental Analysis - Calcd. (%): C 51.89, H 78.30, N 15.14; Found (%): C 51.85, H 8.28, N 15.17. FTIR (cm−1): 3244w (νN−H), 2971 s (νC−H), 2245 s (νC≡N), 1377w (νCH3), 1173 m (νC−C), 608 m (νzn−N) (Figure S1A). Conductance (Ω−1cm2mol−1): 28 (DMSO), 0.0 (CHCl3), 224 (H2O). Magnetic Moment eff (B.M) = 0 (Diamagnetic). 1H NMR (CDCl3, δ ppm): Geminal dimethyl proton, 1.14 (os, 6 H, e), 1.25 (os, 6 H, a), Methyl on chiral carbon, 1.22 (od, 6 H, e), 1.34 (od, 3 H, a), 1.43 (od, 3 H, a); CH2, and CH 2.31(m), 2.75(m), 3.20(m), 3.50(m), and 3.79(m). Diisothiocyanatozinc(II) complex, [Zn(LCX)(NCS)2] 1.0 mmol (0.5549 g) of [Zn(LCX)Cl2] and 2.0 mmol (0.20 g) of KCNS were dissolved separately in 20 mL hot absolute methanol and mixed while hot. The colorless solution thus obtained was heated on a steam bath and completely dried. The dry product was treated with chloroform and filtered off. Evaporation of the chloroform extract gave a solid white product of MP 100 °C, which was stored in a desiccator over silica gel, and characterized as [Zn(LCX)(SCN)2]: MW 600.24. Elemental Analysis - Calcd. (%): C 51.98; H 7.66, N 18.66; Found (%): C 51.96, H 7.64, N 18.65. FTIR (KBr disc, cm−1): 3207w (νN−H), 2971 s, 2933 (νC−H), 2248 (νC≡N), 2083vs (νCN), 1460 m, 1384 s (CH3), 1174 s, 1159 (νC−N,νC−C) (Figure S1B). Conductance (Ω−1cm2mol−1): 0.0 (CHCl3), 40 (DMSO), 194 (H2O). Magnetic Moment µeff (B.M.) = 0 (Diamagnetic). In vitro studies Tumor cell line and maintenance Ehrlich Ascites Carcinoma (EAC) cells were obtained from the Indian Institute of Chemical Biology, Kolkata, India, and maintained in the laboratory by intraperitoneal (i.p.) injections of 3 × 106 cells every two weeks. The donor Swiss albino mouse that carried ascites tumor cells that were between 6 and 7 days old was used to obtain these cells in a fresh extraction. Breast cancer (MCF7) cells were sourced from the American Type Culture Collection (ATCC) and cultured in Dulbecco’s Modified Eagle Medium (DMEM) enriched with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin at 37℃ in a 5% CO₂ environment. Brine shrimp lethality bioassay The assessment of cytotoxicity was conducted using Artemia salina (brine shrimp) nauplii in accordance with a standardized protocol [18]. Artificial seawater was created by dissolving 38 g of NaCl in 1000 mL of distilled water, with the pH adjusted to 7.0 using sodium carbonate. Subsequently, 1 gram of brine shrimp cysts (Artemia salina L.) was added to the solution, which was then incubated at 30 °C with continuous illumination and aeration for a duration of 48 h. After hatching, nauplii were separated and distributed in vials (10 nauplii per vial). Various concentrations of [Zn(LCX)(NCS)2] (0.0, 2.0, 4.0, 6.0, 8.0, 10.0, and 15.0 µg/mL) the dose range of were chosen based on the compound’s solubility in seawater, and the observed cytotoxicity at these concentrations was added to the vials, and the experiment was performed in triplicate. After 24 h, the mortality rate for each treatment group was determined by counting the number of dead organisms. The percent mortality for each concentration was calculated using the following formula: The percent mortality for each experimental concentration was normalized to the control group (0 µg/mL concentration), meaning the observed mortality in each treatment group was adjusted relative to the baseline control group to eliminate any environmental or experimental effects unrelated to the compound. The LC50 value was determined using regression analysis. MTT assay The antiproliferative activity of [Zn(LCX)(NCS)2] against EAC cells was evaluated using the MTT assay in accordance with the established protocol [19]. Shortly, EAC cells (2 × 10⁴ cells/well in 100 µL DMEM) were cultured in 96-well plates and then incubated at 37 °C for a duration of 24 h. Compounds were subjected to serial dilution (20, 50, 100, 200, and 500 µg/mL), and were selected to capture a broad range of the compound’s antiproliferative activity and were used in triplicate, whereas three wells served as untreated controls. After 24 h, the media was aspirated, and 20 µL of MTT reagent (5 mg/ml MTT in PBS) was added. The plates underwent incubation for a duration of 6 h at a temperature of 37 °C, after which 200 µL of acidic isopropanol was added. After 30 min, absorbance was measured at 570 nm. The proliferation inhibition ratio (%) was calculated as: where A and B are the absorbance values of control and TCL-treated cells, respectively. Apoptotic assays in MCF7 cells The evaluation of apoptosis induction in MCF-7 cells by the test compound involved the observation of morphological changes and nuclear damage using a fluorescence microscope (Olympus IX71, Seoul, Korea) as well as an optical microscope [20]. In summary, 96-well plates were populated with cancer cells (5 × 105 cells/well) and incubated for 24 h at 37 °C in an atmosphere containing 5% CO2. After the initial incubations, the cells were treated with the test compound at a concentration of 500 µg/mL and subsequently incubated for an additional 24 h under identical conditions. The cells were then stained with Hoechst 33,342 (0.1 µg/mL) at 37 °C for 20 min, washed, and resuspended in phosphate buffer saline (PBS), and examined for morphological changes indicative of apoptosis, including nuclear damage. mRNA extraction and cDNA synthesis Total RNA was isolated from both untreated and treated MCF7 cells utilizing the FavorPrep™ RNA Purification Mini Kit (Favorgen, Taiwan). The concentration and purity of RNA were assessed using a NanoDrop One spectrophotometer (Thermo Scientific), with A260/280 and A260/230 ratios calculated, while integrity was verified through 1.5% agarose gel electrophoresis. cDNA was generated with the High-Capacity cDNA Reverse Transcription Kit (Promega, Madison-Wiscosin, USA). In summary, a total of 2 micrograms of RNA were converted into cDNA through reverse transcription. The reaction included 1 µL of Random Primer, 2 µL of 2.5 mM MgCl₂, 1 µL of GoScript™ Reverse Transcriptase, 1 µL of PCR Nucleotide Mix (yielding a final concentration of 0.5 mM for each dNTP), 4 µL of GoScript™ 5X Reaction Buffer, and nuclease-free water to achieve a final volume of 20 µL [21]. The synthesized cDNA was then preserved at − 20 °C for subsequent analysis. Real-time quantitative PCR (RT-qPCR) The examination of gene expression in MCF7 cells post-treatment was carried out using cDNA as the template for PCR. The transcriptional profiles of TP53, BAX, BCL2, CASP3, CASP8, CASP9, and PARP1 were assessed using RT-qPCR (LightCycler 96, Roche Diagnostics, Forrenstrasse 2, 6343 Rotkreuz, Switzerland), with glyceraldehyde-3-phosphate dehydrogenase (GAPDH) serving as the internal control [21]. A reaction mixture of 20 µL was formulated, comprising 2x SYBR Green Fast qPCR Mix, 25 pmol primers, and 50 ng cDNA. The RT-qPCR was conducted using a LightCycler 96 System (Roche, USA), starting with an initial denaturation step at 95 °C for 10 min. The procedure involved 45 cycles, with each cycle comprising 15 s at 95 °C for denaturation and 1 min at 60 °C for annealing and extension. Gene expression was measured using the comparative Ct (ΔΔCt) method, normalized to GAPDH. Supplementary information showed the sequences of the primers employed (Table S1). In vivo studies Animal model and ethical approval The study protocol received ethical approval from the Institutional Animal, Medical Ethics, Biosafety and Bio-Security Committee for Experimentations on Animal, Human, Microbes, and Living Natural Sources (No. 293(13)/320-IAMEBBC/IBSc), Institute of Biological Sciences (IBSc), University of Rajshahi, Bangladesh. Swiss albino mice (5–7 weeks old, 25–30 g), were used for in vivo experiments, which were procured from the International Centre for Diarrheal Disease Research, Bangladesh (icddr, b), Dhaka. The mice were kept in metal cages for at least one week before the start of the experiment, with sawdust and straw bedding that was replaced weekly to ensure cleanliness. All mice were housed in standard conditions (12-hour light/dark cycle, 22 ± 2 °C, 50–60% humidity), subjects were given a standard mouse diet (icddr, b) and allowed unrestricted access to clean water. All the methods used in the current study were carried out in accordance with relevant guidelines and regulations. In addition, the maximal tumor size/burden permitted by the institutional ethics committee was 20 g, and the maximal tumor size/burden approved for the current study was not exceeded. Inhibition of EAC cell growth The inhibition of tumor cell growth was evaluated in vivo using a previously established methodology [22]. Three groups of mice (n = 6 per group), each weighing 24 ± 3 g, were used for this study. On day one, each mouse was inoculated with 1.8 × 10⁶ EAC cells. Treatment commenced 24 h after inoculation and was administered daily for five consecutive days. Mice in Groups 1 and 2 received intraperitoneal injections of the test compound at doses of 100 µg/kg and 200 µg/kg per day, respectively, contained in 0.1 mL solution. The 200 µg/kg/day dose for in vivo studies was selected based on preliminary toxicity studies, solubility, and pharmacokinetics, aiming to achieve effective tumor inhibition while minimizing toxicity. Group 3, serving as the untreated control, was given an equivalent volume of normal saline. On the sixth day after inoculation, the mice were sacrificed, and tumor cells were harvested by performing multiple intraperitoneal washes with 0.9% saline solution. EAC cells were assessed for viability using the trypan blue exclusion method and counted with a hemocytometer under an inverted microscope (XDS-1R, Optika, Bergamo, Italy). The number of viable tumor cells per mouse in the treated groups was then compared with that of the control group. The percentage of cell growth inhibition was calculated using the following formula: Here, Tw represents the mean number of tumor cells in the treated group, and Cw represents the mean number of tumor cells in the control group. Assessment of ascites tumor burden and survival time Survival time and ascites tumor burden were evaluated following the previously described protocol [23]. The control group (Group 1) received normal saline. In Groups 2, treatment with the test compound was initiated 24 h post-inoculation via intraperitoneal injection at doses of 200 µg/kg body weight, and continued for a duration of 10 days. The body weight of each mouse was monitored every 48 h, with observations continuing for up to 25 days following tumor inoculation. Mice with ascites tumors in the peritoneal cavity showed an increase in body weight due to tumor growth, and, thus, the tumor burden was measured by subtracting the initial weight of mice on day zero of EAC inoculation at each time point. The weight measurements were used as an indirect indicator of tumor progression. Survival analysis was performed using Kaplan–Meier survival curves to assess the survival rate of EAC-bearing mice over time [24]. Mice were monitored daily for survival, and the percent survival was plotted against time (days). Statistical comparisons between survival curves were made using the log-rank test. A p-value of < 0.05 was considered statistically significant. Survival duration was tracked and reported as the mean survival time (MST) in days. The percentage increase in life span (% ILS) was calculated using the following equation: Assessment of hematological parameters of EAC-bearing mice The impact of the test compound on hematological parameters specifically white blood cells (WBC), red blood cells (RBC), and hemoglobin (Hb) was evaluated using a standard procedure involving appropriate cell dilution fluids and a hemocytometer [25]. The study included three groups of mice: a normal group (non-tumor-bearing), a control group (EAC-bearing without treatment), and one experimental group bearing EAC and treated with the test compound at a dose of 200 µg/kg body weight per day. The compound was administered intraperitoneally for 10 consecutive days. Each group comprised six mice. On day 0, EAC cells (0.1 mL containing 1.6 × 10⁶ cells/mouse) were injected intraperitoneally into each of the groups. After a 24-hour incubation period, treatment with the test compound commenced. On the 11th day post-treatment, blood was collected from the tail vein into tubes containing anticoagulant, and WBC, RBC, and Hb levels were measured as previously described [25]. Toxicity studies Assessment of hematological parameters of normal mice The effect of the test compound on the hematological profile of normal mice was assessed to detect any potential abnormalities. Standardized procedures involving cell dilution fluid were employed to measure hematological parameters, including white blood cell (WBC) count, red blood cell (RBC) count, and hemoglobin (Hb) concentration [26]. In this study, two experimental groups were taken; Group 1(n = 6) comprised normal healthy mice serving as the control group, and Group 2 (n = 18) included normal healthy mice that received the test compound at a dose of 200 µg/kg body weight per day for 10 days, through intraperitoneal (i.p.) injection. Blood samples were obtained from each group 1 on day 0, and group 2 on days 5, 10, and 25, and hematological analysis was performed in accordance with established methodologies [21, 25]. Assessment of biochemical parameters of normal mice Biomarkers of hepatic function, such as aspartate aminotransferase (SGOT) and alanine aminotransferase (SGPT), as well as renal function indicators, including serum creatinine, glucose, and cholesterol, were measured quantitatively. On days 0, 5, 10, and 25, all mice were anesthetized and euthanized by exact excision with surgical blade No. 22. Blood samples were placed in sterile centrifuge tubes and allowed to coagulate at 37 °C for 4 h. After coagulation, the samples were centrifuged at 4000 rpm for 15 min on a WIFUNG LABO-50 M centrifuge. The resulting clear, straw-colored serum was carefully aspirated using a Pasteur pipette and refrigerated at −20 °C to ensure preservation. Biochemical parameters were determined using validated commercial assay kits and a Humalyzer 3000 bioanalyzer (HUMAN Diagnostics Worldwide, Wiesbaden, Germany), as per the manufacturer’s instructions. Histopathology To assess the impact of the test compound on the tissue section, histological analysis of key organs such as the heart, lung, liver, kidney, and spleen was conducted to identify any alterations, including inflammation, degradation, regeneration, congestion, infiltration, and more. The experiment involved two cohorts of Swiss albino mice as described above. The organs were gathered on the 25th day, and tissue samples were preserved in 10% formal saline, subsequently processed using the standard paraffin embedding technique [21]. Slides were prepared by cutting sections of five-micron thickness and staining them using the Haematoxylin and Eosin (H&E) method. The slides were examined utilizing the Motic Advanced system microscope (B, series) in conjunction with Motic J.1 software. Statistical analysis The number of biological replicates (n) for each dataset was as follows: In vitro studies: n = 3, each performed in triplicate. In vivo studies: n = 6 mice per group. The data are expressed as mean ± SEM. Statistical analysis was conducted employing an unpaired t-test and one-way ANOVA, followed by Duncan’s multiple range test for subsequent post hoc comparisons. All analyses were performed utilizing GraphPad Prism 8.2.0 and IBM SPSS Statistics 20, with statistical significance established at p < 0.05. Results Characterization of the precursor Dichloridozinc(II) complex: [Zn(LCX)Cl2] The interaction of the ligand, LCX, with zinc(II) chloride yielded a sticky product, which, upon treatment with methanol and extraction with chloroform, resulted in a white product. Elemental analysis, IR spectral data, molar conductance data, and 1H-NMR spectral data fully support the complex having the molecular formula [Zn(LCX)Cl2]. The infrared spectrum (Figure S1A in Supporting Information) of this complex showed characteristic νN−H, νC−H, νCH3, νC−C, and νC≡N, bands presented in Table 1. Table 1 also compares the IR bands of the complex with those of the pure ligand (LCX) published in a previous paper [16]. Since the IR spectrum could not be run below 450 cm− 1, the bands for Zn-N and Zn-Cl could not be detected. However, strong evidence for coordination is displayed by the following: Table 1IR spectroscopic assignments of the Dichloridozinc(II) complex: [Zn(LCX)Cl2]Functional groupVibrational modeComplex ([Zn(LCX)Cl2]) (cm− 1)Ligand (LCX)/cm− 1Coordination effect ()Secondary amine N−H stretching3400 (broad), 3244 (weak), 3159 (med)3240 (strong)Strongly Affected (Evidence of coordination)Nitrile stretching22452245Zero shift (): Non-coordinatingAliphatic C−H stretching2971, 2936, 28822962Minimal change (inductive shift/solid-state effects)Secondary amine N−H bending1659, 1582No ligand reportedSplit bands: Confirms non-equivalent N−H environmentAliphatic C−H deformation (CH3 sym.)1470, 13771369Slight shift (due to macrocycle rigidity/coordination strain)Skeletal C−N stretching1174. 11611168, 1141Small shifts (Change in ring conformation/strain upon coordination) IR spectroscopic assignments of the Dichloridozinc(II) complex: [Zn(LCX)Cl2] Nitrile i.The appearance of the 3159 cm− 1 band in the spectrum of the complex, representing a significant down-shift from the free ligand’s 3240 cm− 1, confirms the coordination of the N atom to Zn2+. The appearance of the 3159 cm− 1 band in the spectrum of the complex, representing a significant down-shift from the free ligand’s 3240 cm− 1, confirms the coordination of the N atom to Zn2+. ii.The complete lack of shift for the band (2245 cm−1 in both) definitively confirms the non-coordination of the cyano-ethyl side arms to the metal center. The complete lack of shift for the band (2245 cm−1 in both) definitively confirms the non-coordination of the cyano-ethyl side arms to the metal center. iii.The clear splitting and shift of the bending modes (1659 & 1582 cm− 1) confirm the loss of symmetry and non-equivalence of the amine N-H groups, which is characteristic of a distorted octahedral structure where the macrocycle ligand (which is typically strained) and the two axial chloride ligands force the Zn(II) center into a non-ideal geometry. The clear splitting and shift of the bending modes (1659 & 1582 cm− 1) confirm the loss of symmetry and non-equivalence of the amine N-H groups, which is characteristic of a distorted octahedral structure where the macrocycle ligand (which is typically strained) and the two axial chloride ligands force the Zn(II) center into a non-ideal geometry. Furthermore, the molar conductivity of the complex [Zn(LCX)Cl2] was measured to be 28 Ω−1cm2mol−1 in dimethyl sulfoxide (DMSO) solution. This low value is consistent with a non-electrolyte, confirming that the two chloride ligands are coordinated to Zn2+ ions, thus supporting a six-coordinate octahedral geometry for the complex. When dissolved in water, however, the complex exhibits a molar conductivity of 224 Ω−1cm2mol−1. This value is typical for a 1:2 electrolyte, suggesting that the original chloride ligands have been displaced by water molecules. This process, known as aquation, results in the formation of a diaquo complex, as illustrated by the schematic representation below: The 1H-NMR spectrum of this complex has been presented in Figure S2 of the Supporting Information. The extracted ¹H NMR data are presented in Table 2, which strongly supports the low-symmetry, six-coordinate distorted octahedral structure inferred from IR and conductivity. The critical evidence lies in the non-equivalence of the methyl protons: the 12 H of the gem-dimethyl groups resolve into two 6 H singlets (δ 1.14 and 1.25 ppm), and the 12 H of the C-methyl groups split further into distinct doublets (6 H:3 H:3 H pattern). This extensive signal splitting confirms that the N−H protons and all C-methyl groups reside in non-equivalent magnetic environments, consistent with the highly constrained diaxial-diequatorial macrocycle conformation within the coordination sphere. Crucially, the N−H signal is not the peak at δ7.26 ppm (which is residual CHCl3 impurity), but its N atom is confirmed to be coordinating by the IR data, which showed a significant down-shift to 3169 cm− 1. The N−H proton’s signal is therefore expected to be shifted upfield and is obscured by overlap or exchange within the complex aliphatic region (2.41−3.79 ppm). Table 21H-NMR spectral data for [Zn(Lcx)Cl2]ComplexTypes of protonsGeminal dimethyl (δ, ppm)Methyl on chiral carbon (δ, ppm)CH2, CH, NH (δ, ppm)[Zn(Lcx)Cl2]1.14 (os, 6 H, e)1.25 (os, 6 H, a)1.22 (od, 6 H, e)1.34 (od, 3 H, a)1.43 (od, 3 H, a)2.41 (m), 2.75(m)3.32(m), 3.50(m)3.79(m) 1H-NMR spectral data for [Zn(Lcx)Cl2] 1.14 (os, 6 H, e) 1.25 (os, 6 H, a) 1.22 (od, 6 H, e) 1.34 (od, 3 H, a) 1.43 (od, 3 H, a) 2.41 (m), 2.75(m) 3.32(m), 3.50(m) 3.79(m) The totality of the evidence robustly supports the assignment of a six-coordinate distorted octahedral geometry. The NMR and IR splitting patterns (non-equivalent CH3 and N-H environments) confirm the low symmetry. The IR also confirms the coordination of the four amine N atoms and the non-coordination of the C ≡ N pendant arms (2245 cm− 1). Finally, the DMSO conductivity (28 Ω−1cm2mol−1) confirms the necessary coordination of both chloride ions to complete the ZnN4Cl2 octahedral core in the solid state. This compelling evidence leads to the unambiguous assignment of the complex as the distorted octahedral species [Zn(LCX)Cl2], corresponding to structure 1 A in Scheme 1. Structure of the precursor complex [Zn(Lcx)Cl2] (1 A) and the test compound [Zn(LCX)(NCS)2] (1B) Characterization of the test compound, Diisothiocyanatozinc(II) complex: [Zn(LCX)(NCS)2] The precursor Dichloridozinc(II) complex, [Zn(LCX)Cl2], was converted into the test compound Diisothiocyanatozinc(II) complex, [Zn(LCX)(NCS)2], by an axial ligand substitution reaction, as detailed in the Materials and Methods section. [Zn(LCX)(NCS)2], is definitively characterized as a six-coordinate distorted octahedral species (Structure 1B, Scheme 1), maintaining the low-symmetry diaxial-diequatorial macrocycle conformation of its precursor. The IR spectrum of the complex is displayed in Figure S1b of the Supporting Information, and assignments of the corresponding IR bands are presented in Table 3. This Table provides direct evidence for the axial NCS coordination: the sharp νCN band at 2083 cm− 1 confirms the N-bonded isothiocyanate linkage (M-NCS). The macrocycle’s coordination is confirmed by the band at 3207 cm− 1, and its low symmetry is proven by the splitting of the δN−H bending modes (1664 and 1601 cm− 1. Table 3IR spectroscopic assignments of the Diisothiocyanatozinc(II) complex: [Zn(LCX)(NCS)2]Functional group/areaFrequency (cm− 1)Vibrational mode assignmentCoordination implicationThiocyanate ligand NCS2083 (Very Strong, Sharp) stretchingDefinitive evidence for N-coordination (isothiocyanate)Pendant nitrile 2248 (Weak, Sharp) stretchingConfirms non-coordination of the cyano-ethyl arms (no significant shift from the free ligand 2245 cm− 1Secondary amine N–H3450 (Strong, Broad) (H2O)/Free StretchingLikely trace moisture/weak N – H3207 (Medium, Broad)Coordinated StretchingConfirms N coordination to Zn2+1664 (Strong)1601 (Strong) BendingSplitting confirms low-symmetry/non-equivalent N-H groups in the distorted octahedral coreAliphatic C–H2971 (Medium, Sharp), 2933 (Weak Shoulder) Stretching (CH3, CH2)Standard aliphatic groups; unaffected by coordination.1460 (Medium) Deformation (CH2 Scissoring)Standard aliphatic deformation1384 (Strong, Sharp) Deformation (CH3 Symmetric Bending)Characteristic CH3 group vibrationMacrocycle skeletal1174 (Sharp), 1159 (shoulder) Confirms macrocycle integrity and rigidity imposed by coordination IR spectroscopic assignments of the Diisothiocyanatozinc(II) complex: [Zn(LCX)(NCS)2] 1664 (Strong) 1601 (Strong) The conductance data (presented in Table S2) of the test compound confirm the stability of the coordination sphere: the complex is a non-electrolyte in CHCl3 (0 Ω−1cm2mol−1), requiring both NCS− ligands to be coordinated (as in Structure 1B of Scheme 1). While the DMSO conductivity of 40 Ω−1cm2mol−1 suggests a partial equilibrium with a five-coordinate square-pyramidal cation Zn(LCX)(NCS)]+ via displacement of one of the NCS− ligands. The high value of 194 Ω−1cm2mol−1 in water confirms the complex readily undergoes complete aquation. to the 1:2 electrolyte, [Zn(LCX)(H2O)2]2+. Coupled with the expected diamagnetic character (eff (B.M.) = 0, consistent with d10 Zn2+), the evidences lead to the unambiguous assignment of [Zn(LCX)(NCS)2] as the distorted octahedral species, Structure shown in scheme 1B. In vitro studies Brine shrimp lethality bioassay The cytotoxic effects of the test compound diisothiocyanatozinc(II) complex, [Zn(LCX)(NCS)₂], were evaluated through the brine shrimp lethality bioassay. The median lethal concentration (LC₅₀) has been determined to be 7.734 µg/mL. (Fig. 2A). Cytotoxicity of Zn (II) complex. A Effect of the compound on brine shrimp nauplii. The compound exhibited potent cytotoxicity against brine shrimp nauplii with an LC50 value of 7.734 µg/mL. B The compound demonstrated a strong inhibitory effect on the proliferation of MCF7 breast cancer cells in a dose-dependent manner in vitro. Each experiment was carried out in triplicate (n = 3), biological and technical replicates, and the results are expressed as mean ± SEM. Statistical significance was determined by one-way ANOVA followed by Duncan’s multiple range test for pairwise comparisons In vitro growth inhibition of MCF7 cells The test compound demonstrated a potent inhibitory effect on the proliferation of MCF-7 breast cancer cells, accompanied by a dose-dependent growth inhibition of cancer cells with an IC50 of 252.43 µg/mL (Fig. 2B). The compound showed a peak suppression of cell proliferation at 85% when administered at a 500 µg/mL concentration. In contrast, the lowest level of inhibition recorded was 11% at a concentration of 20 µg/mL, relative to the untreated control group (Fig. 2B). Induction of apoptosis of MCF7 cells In the control group, MCF7 cells exhibited consistent, rounded, and uniform nuclear staining when observed under a fluorescence microscope, subsequent to Hoechst 33,342 staining (Fig. 3A). Conversely, cells exposed to the compound (500 µg/mL) displayed characteristics of apoptosis, including membrane blebbing and condensed, fragmented nuclear material (Fig. 3B). In a similar manner, observations made using a phase-contrast microscope revealed that control MCF7 cells did not display any formation of apoptotic bodies, whereas those subjected to the treatment exhibited such formations (Fig. 3C & D). Morphological alteration of MCF7 cells treated with Zn (II) complex. A Control MCF7 cells under a fluorescence microscope, followed by Hoechst 33,342 staining. B Treated cells exhibited apoptotic features such as membrane blebbing, condensed, and fragmented nuclear material. C Control MCF7 cells under a phase-contrast microscope, D Treated MCF7 cells under a phase-contrast microscope. Arrows indicated the apoptotic cells in the treated group Upregulation of apoptotic pathways in cancer cells by [Zn(LCX)(NCS)2] We have observed a significant alteration in the expression of genes related to apoptosis in MCF7 cells following exposure to the test compound. Figure 4A demonstrates that the pro-apoptotic genes (p53, Bax, Caspase 3, Caspase 8, Caspase 9, and PARP1) show significant upregulation in the treatment group compared to the control (P < 0.001), expressed by gene expression ratio. We also analyzed the 2-ΔΔCt fold-change values (normalized to the untreated control = 1) for these genes are shown in Fig. 4B. As shown in Fig. 4B, all treated groups exhibited significant upregulation of the pro-apoptotic markers, with p-values less than 0.05 for p53 (p = 0.001), Bax (p = 0.01), and PARP1 (p = 0.004). Error bars represent SEM calculated from three biological and two technical replicates, highlighting a notable increase in the activation of apoptotic pathways. Conversely, the expression of the anti-apoptotic gene Bcl2 is significantly diminished in the treatment group, thus promoting apoptosis (Fig. 4). A Expression analysis of apoptotic genes in MCF7 cells. The assessment of relative mRNA expression levels for p53, BAX, BCL2, CAS3, CAS8, CAS9, and PARP1 was conducted in vitro using cultured MCF7 cells, comparing both untreated and compound-treated conditions. Isolation of total RNA was performed, followed by reverse transcription to generate cDNA. This cDNA served as the template for quantitative PCR (qPCR) analysis utilizing SYBR Green Master Mix. Gene expression was quantified relative to the housekeeping gene GAPDH, utilizing the ΔΔCt method for normalization. B 2-ΔΔCt fold-change normalized to control = 1 Gene expression analysis of pro-apoptotic markers in treated and control groups. The 2-ΔΔCt fold-change in gene expression for pro-apoptotic markers (p53, Bax, Caspase-3, Caspase-8, Caspase-9, PARP, and Bcl2) was measured by qPCR. Data are expressed as mean ± SEM from three independent biological replicates. Gray bars represent the control group, while black bars represent the treatment group. Upregulation of pro-apoptotic genes (Bax, Caspase-3, Caspase-8, Caspase-9, and PARP) and downregulation of Bcl2 were observed in the treatment group. The determination of statistical significance was achieved through the application of a two-way ANOVA test (P < 0.05), *p < 0.05,**p < 0.01, and ***p < 0.001 In vivo studies Inhibition of EAC cell growth Suppression of in vivo tumor cell growth was observed with the test compound, administered at two different doses (100 µg and 200 µg/kg body weight) per animal daily, as illustrated in Fig. 5A and B. The viable EAC cell count showed a significant decrease at both treatment concentrations when compared to the control group (p < 0.001). Furthermore, the administration of the 200 µg/kg dosage led to the highest level of cell growth inhibition (86%) in comparison to the control group (p < 0.001). In contrast, the test compound at 100 µg/kg achieved a reduction in cell growth of 79.41% when evaluated against untreated EAC-bearing subjects (Fig. 5B). In vivo anti-tumor activity of Zn (II) complex against EAC cells. A Number of viable EAC cells in control, compound treated (100, 200 µg/body weight/day); B percentage of EAC cell growth inhibition at the doses of 100, 200 µg/body weight/day; C Effects of compound on survival (Mean Survival Time, MST) of EAC-bearing experimental mice; D Kaplan–Meier survival curves for EAC-bearing mice treated with different doses control (blue), a low dose (purple), or a high dose treatment (teal) of the compound. Survival was monitored over 40 days, and data are presented as percent survival with error bars indicating standard error. Log-rank test was used to compare survival between the groups, with significant differences observed between the treatment groups and the control. E Ascites tumor burden in EAC-bearing mice. Each group contained n = 6 animals. The data are expressed as mean ± SEM. Statistical significance was assessed by one-way ANOVA followed by Duncan’s multiple range test for pairwise comparisons, with p < 0.001 and p < 0.0001 indicating significant differences between treated and control groups Average ascites tumor burden and survival duration Figure 5C illustrates the impact of [Zn(LCX)(NCS)₂] on the survival rate of the tumor-bearing mice in the treated and untreated groups. A treatment dosage of 200 µg/kg led to a noticeable improvement in lifespan, showing an increase of 60.3% (p < 0.001) when compared to the control group. Figure 5D Kaplan–Meier survival curves were generated for each group (control, low dose, high dose) to evaluate the impact of the treatment on survival. The high-dose treatment group showed a significant improvement in survival compared to the control group (log-rank test, p < 0.01). The low-dose group demonstrated extended survival compared to controls, but this difference was not statistically significant (p > 0.05). These results indicate that the higher dose of the compound may offer more effective survival benefits in EAC-bearing mice. Figure 5E presents the effect of the compound on average ascites tumor burden, which reveals a notable distinction in ascites tumor burden gain between the control and treated groups. On day 20, control mice bearing EAC showed a 42.42% increase in ascites tumor burden, whereas those treated with 200 µg/kg of the compound displayed a significantly lower weight gain of 19.09% (P < 0.001). Additionally, the tumor burden in the control group showed an increase of 8.48 g on day 20 in comparison to normal mice. Conversely, the administration of a higher dose (200 µg/kg i.p.) limited the increase in ascites tumor burden to just 3.81 g. This demonstrates a threefold decrease in ascites tumor burden in the high-dose treatment group when compared to the untreated EAC-bearing mice. Hematological profile of EAC-bearing mice Figure 6 shows the effect of the complex on hematological parameters such as RBC, WBC, and hemoglobin levels in normal, EAC-bearing control, and compound-treated mice (Figure 6). Treatment of EAC-bearing mice with the compound significantly improved the blood parameters when compared to EAC-bearing mice (Figure 6). Effect of [Zn(LCX)(NCS)2] complex on hematological parameters of EAC cell-induced Swiss albino mice. Bar graphs represent the levels of (A) white blood cells (WBC), (B) red blood cells (RBC), and (C) hemoglobin (Hb) in control and treated groups. Data are expressed as mean ± SEM (n = 6). EAC-bearing mice exhibited altered hematological profiles, with the treated group showing partial restoration toward normal values. Statistical significance was assessed using one-way ANOVA followed by Duncan’s multiple range test, with *p < 0.05 and ****p < 0.0001 when compared to untreated normal mice Toxicity studies Hematological profile of normal animal The effects of the test compound on hematological parameters in Swiss albino mice, given a dosage of 200 µg/kg body weight/day/mouse (i.p.) for 10 consecutive days, are illustrated in Fig. 7 for days 0, 5, 10, and 25. The findings revealed a moderate rise in the WBC value during the administration of the test compound on day 5, which was subsequently followed by a gradual decline after the treatment was halted on days 10 and 25. However, there were no noticeable changes in the RBC and hemoglobin levels when analyzed against the normal and treatment groups of mice (Fig. 7). Effects of the [Zn(LCX)(NCS)2] complex on hematological parameters in normal mice. Bar graphs depict the levels of (A) white blood cells (WBC), (B) red blood cells (RBC), and (C) hemoglobin (Hb) measured in normal (untreated) mice and treated groups on day 5, day 10, and day 25 following repeated administration of the compound for 10 days. The study aimed to assess the sub-acute hematological toxicity profile of the test compound over time. The results are expressed as mean ± SEM (n = 6). Statistical significance was determined using one-way ANOVA followed by Duncan’s multiple range test, with p < 0.05 when compared to the control Biochemical profile Figure 8 shows the effect of the complex on various biochemical parameters such as glucose, creatinine, SGOT, SGPT, and cholesterol levels. Swiss albino mice received a dosage of 200 µg/kg body weight over a period of 10 consecutive days, with measurements of the parameters conducted on days 5, 10, and 25. The glucose graph demonstrates that normal mice maintained consistent glucose levels (~ 120 mg/dl), but the treated group started at a lower level (~ 100 mg/dl) and steadily climbed over time, indicating a moderate influence on glucose metabolism. Normal mice had constant creatinine levels, while the treatment group experienced a dramatic increase by day 10 (~ 1.1 mg/dl), followed by a drop, but remained slightly elevated relative to normal mice. This shows that the therapy caused transitory renal stress, which had partially recovered by day 25. Moreover, the control group’s SGOT levels remained steady at roughly 80 U/L, falling within the normal range. The treatment group initially replicates the control group, but by day 10, there was a substantial decrease in SGOT levels, indicating a transitory benefit of the treatment. However, the levels return to baseline by day 25. The graph depicts SGPT levels over a 25-day period, indicating a constant level of around 13 U/L in the normal control group, but the treatment group fluctuated, peaking at approximately 16 U/L by day 10, declining to around 10 U/L by day 15, and then recovering to near baseline by day 25. At the 25-day endpoint, a statistically significant difference (p < 0.001) was seen between the groups, indicating that the therapy caused a transitory alteration in SGPT levels, despite the fact that both groups eventually converged to similar values. Finally, the graph displays cholesterol levels throughout 25 days, with the normal control group maintaining a consistent level of 165–167 mg/dl. In contrast, the therapy group showed a significant decrease in cholesterol levels, decreasing to around 152 mg/dl by day 10 and then to 138 mg/dl by day 15, before returning to near baseline levels of around 168 mg/dl by day 25. As a result, the treatment caused a brief drop in cholesterol levels, with a complete recovery at the end of the 25 days (Figure 8). Effect of the complex on the biochemical parameters of animals. Normal mice were examined on various days following a 10-day treatment period for serum creatinine, glucose, cholesterol, SGOT, and SGPT. These parameters experience a degree of decline during the treatment period; however, they return to their pre-treatment levels. The mean ± SEM is presented, and the significant values are p < 0.05 when compared to the control. Effect of the test compound on biochemical parameters in mice (in vivo toxicity study). Serum creatinine, glucose, SGOT, SGPT, and cholesterol in normal mice. The results are expressed as mean ± SEM (n = 6). Statistical significance was determined using one-way ANOVA followed by Duncan’s multiple range test, with p < 0.05 when compared to the control Histology Histological examination of the tissues from key organs (such as the liver, kidney, lungs, spleen, and heart) in both control mice and those subjected to the treatment over a consecutive 10-day period revealed no signs of damage (including degeneration or regeneration) when compared to the control (normal) mice (Fig. 9). Effect of test compound on tissue level of major organs of Swiss albino mice. The mice were treated with the complex for 10 consecutive days at a dose of 200 µg/kg of body weight/mouse/day. Histological analysis of the tissue sections did not exhibit any notable changes (degeneration/regeneration) in the tested organs of the animals Discussion Metal-based chemotherapeutic agents play a crucial role in cancer treatment; however, their widespread clinical use is often limited due to severe toxicity, high costs, and limited accessibility. Considering these challenges, our research focused on developing alternative chemotherapeutic compounds with minimal side effects. This study successfully synthesized and characterized a novel di-isothiocyanatozinc(II) complex, [Zn(LCX)(NCS)2], and comprehensively tested the compound’s antineoplastic activity using both in vitro and in vivo methods. The brine shrimp lethality bioassay revealed a potent cytotoxic effect for the test compound, [Zn(LCX)(NCS)2], with an LC₅₀ value of 7.734 µg/mL. This dose-dependent response suggests a promising biological activity. When comparing this result to the previously reported LC₅₀ values for the analogous Rh-complex (25.90 µg/mL) and Ni-complex (23.73 µg/mL), a clear trend emerges regarding the relative cytotoxic potencies of these metal complexes (Table S3) [21, 27]. The lower LC₅₀ value of the Zn-complex (7.734 µg/mL) signifies that it is significantly more toxic to brine shrimp larvae than either the Rh- or Ni-complexes. Quantitatively, the Zn-complex is approximately more than 3 times more potent than both the Rh- and the Ni-complex, positioning it as a more promising lead compound for further investigation into its potential as a pharmaceutical agent, particularly in the context of anticancer applications. In in-vitro studies on the MCF-7 cell line, the compound exhibited a maximum suppression of cell proliferation (85%) at a dose of 500 µg/mL, whereas the minimum inhibition recorded was 11% at 20 µg/mL, compared to the control. However, the compound exhibited a higher IC50 value of 252.43 µg/mL against human breast cancer (MCF7) cells, indicating better host toxic nature of the compound. In contracts, Ni- or Rh-complexes exhibited strong toxicity, 71.5 and 81.6 µg/mL, against MCF7 cells, respectively. The test compound demonstrated a significant effectiveness in eliminating EAC cells in vivo in Swiss albino mice, as evidenced by a substantial reduction in cellular proliferation. The observed inhibitory effect, which peaks at 86.54%, highlights the significant anticancer potential, whereas it shows 79.41% growth inhibition at a lower dose (100 µg/mL). Accordingly, the Rhodium complexes exhibited considerable tumor shrinkage, diminished ascites tumor burden, and prolonged survival in EAC-induced mice, underscoring their therapeutic efficacy [21, 28–30]. Similarly, our investigation of the diisothiocyanatozinc(II) complex, [Zn(LCX)(NCS)₂], demonstrated a significant anticancer cell growth inhibition Also, our findings indicated a substantial reduction in tumor burden, evidenced by a threefold decrease in ascites tumor burden in the high-dose treatment group and a notable 73.4% increase in survival time of EAC-bearing animals. Although 85% inhibition of MCF7 cell proliferation at 500 µg/mL in the in vitro MTT assay, while in vivo studies showed an 86% tumor growth inhibition at 200 µg/kg/day. These results suggest that the compound has potent antitumor activity in both models, but the difference in inhibition between in vitro and in vivo conditions could be due to factors such as bioavailability, absorption, and metabolic processes. The similarity in the inhibition observed in both models indicates that the compound retains substantial activity despite these challenges, and future work may focus on improving formulation or delivery strategies to enhance bioavailability and targeted delivery. It is important to highlight that structurally similar complexes, such as those of Cu(II), Rh(II), and Mn(II) coordinated with 5-Chloro-2-N-(2-quinolylmethylene) aminophenol, demonstrated notably reduced inhibitory activity against EAC cells (Table S3) [16, 27]. In addition, the compound reduced the tumor burden of EAC-bearing mice significantly, similar to that of other potential therapeutic agents [21, 24–27]. In the survival analysis, Kaplan–Meier survival curves revealed that the high-dose treatment significantly improved the survival of EAC-bearing mice compared to the control group (log-rank test, p < 0.01), suggesting that higher doses of the compound may offer therapeutic benefits. The results indicate that the compound exhibits notable anticancer properties while maintaining high efficacy at reduced dosages, thereby minimizing the likelihood of toxicity and side effects typically linked to higher-dose therapies. The increased potency observed could be linked to its distinctive coordination chemistry, enhanced cellular uptake, or more robust interactions with the molecular targets that play a role in tumor growth and progression. The study of hematological parameters is essential for assessing the effectiveness and safety of prospective anticancer agents in models of EAC-induced cancer [26]. The occurrence of cancer-induced anemia arises from either hematopoietic suppression or the inhibitory effects of cytokines on RBC production [31]. This results in a significant reduction in hemoglobin and RBC levels, contrasted by an increase in WBC counts, which is attributable to inflammation associated with tumors [32]. Previous study indicates that the administration of a Rhodium/nickel complex has led to notable enhancements in hemoglobin and RBC levels, alongside a decrease in WBC counts in tumor-bearing mice, implying a potential protective role for the haematopoietic system [21, 30]. Similarly, our study on Zn(II) complex revealed a partial restoration of RBC levels (7.35 × 10⁹ versus 4.4 × 10⁹ cells/ml) and hemoglobin concentrations (7.4 versus 6.0 g/dl), alongside a reduction in WBC count (3.2 × 10⁶ cells/ml). The treatment restored approximately 40% of the RBC level and 20% of the Hb levels. These findings suggest a potential role in alleviating tumor-associated hematological changes. It is important to note that conventional chemotherapy has been associated with the induction of anemia. The European Cancer Anemia Survey reveals a notable rise in the prevalence of anemia, escalating from 19.5% in the initial cycle of chemotherapy to 46.7% by the fifth cycle [32]. Additionally, another investigation suggests that the occurrence could rise to as much as 90% after administration of chemotherapeutic agents [33]. In light of these challenges, the findings regarding [Zn(LCX)(NCS)₂] suggest its capability to restore hematological balance without adverse effects. This underscores its potential as a safer and more tolerable alternative. Additional investigation is necessary to elucidate the mechanism by which it safeguards hematopoietic function while demonstrating significant anticancer properties. Apoptosis evasion is a key feature of cancer, allowing for uncontrolled cell proliferation and tumor growth. Thus, inducing apoptosis selectively in cancer cells while preserving normal cells is an important strategy for designing safer and more effective anticancer drugs [20, 34]. Previous research has shown that a Rhodium complex successfully induces apoptosis in MCF-7 breast cancer cells, indicating a possible anticancer strategy [21]. Our work found that [Zn(LCX)(NCS)2] complex effectively inhibited MCF-7 cell proliferation and induced apoptosis in a dose-dependent manner. The activation of apoptotic pathways is critical in determining the success of anticancer therapies. Previous research has shown that apoptosis is carefully regulated by a balance of pro- and anti-apoptotic proteins, particularly those in the Bcl-2 family [20, 30, 34]. The overexpression of Bax and downregulation of Bcl-2 are important markers for apoptosis induction, with an elevated Bax/Bcl-2 ratio promoting mitochondrial membrane permeabilization and cytochrome C release. This cascade then activates caspase-9, which initiates apoptosis via caspase-3. However, MCF7 cells lack functioning caspase-3, implying that other mechanisms, such as PARP cleavage, may contribute to apoptosis execution [35, 36]. Our study found that treatment with the [Zn(LCX)(NCS)2] complex significantly increased key pro-apoptotic genes, including p53, Bax, Caspase-9, and PARP1, while downregulating Bcl-2, confirming the activation of the intrinsic apoptotic pathway. The overexpression of PARP1 indicates increased DNA damage, which promotes apoptosis. Furthermore, although caspase-8 expression increased in response to treatment, the difference was not statistically significant (p >0.05), indicating that, while the extrinsic apoptotic pathway may be activated, it is unlikely to be the predominant cause of cell death in MCF7 cells. However, the observed rise in caspase-8 levels indicates that extrinsic and intrinsic mechanisms may interact via Bid cleavage. These findings suggest that [Zn(LCX)(NCS)₂] fights cancer by activating both the intrinsic and extrinsic apoptotic pathways. These findings emphasize the compound’s therapeutic potential in breast cancer treatment and call for additional exploration into its molecular connections with apoptotic signaling pathways. A key phase in the development of any therapeutic substance is the evaluation of its health and safety profile. We assessed the sub-acute toxicity of the complex in Swiss albino mice. Following 10 consecutive days of intraperitoneal treatment, we analyzed hematological and biochemical parameters on days 5, 10, and 25. Our findings align with earlier research, as red blood cell (RBC) and hemoglobin levels remained steady throughout the study period, indicating that the substance does not induce significant hematotoxicity [21, 30, 34]. The WBC counts exhibited a moderate increase during the treatment period (days 5 and 10), aligning with the temporary elevation observed in earlier studies and suggesting a slight immune response or inflammatory reaction [21, 30, 34]. However, by day 25, WBC levels had restored to near-normal levels, indicating that the treatment did not induce long-term haematological abnormalities. Biochemical tests indicated that [Zn(LCX)(NCS)2] did not cause significant fluctuations in biochemical parameters. Glucose levels in treated mice initially fell but eventually recovered to normal levels over time, consistent with prior observations in which glucose metabolism was unaffected by treatment. Interestingly, our study found a transitory increase in creatinine levels by day 10, followed by partial recovery by day 25, indicating recovery from temporary renal stress. In contrast, previous investigations on metal complexes found no significant changes in creatinine levels. It implies that renal effects may be compound-specific and deserve additional exploration [21]. The liver function markers SGOT and SGPT varied over the treatment period but reverted to normal by day 25, indicating that any hepatic stress caused by the medication was reversible. This finding is consistent with prior research, which found that SGOT and SGPT levels exhibited moderate, transitory alterations without causing chronic liver damage [21, 30]. Furthermore, cholesterol levels in our trial dropped briefly following treatments but returned to normal levels by day 25. Unlike prior studies where cholesterol levels remained steady, [Zn(LCX)(NCS)2] may have a short-term impact on lipid metabolism. Furthermore, the tissue analysis revealed no significant damage to major organs such as the liver, kidneys, spleen, lungs, or heart throughout the treatment, suggesting that the compound does not pose potential long-term toxic effects on the primary organs of the animal. Although there was a fluctuation in the serum creatinine level on day 10, it returned to a normal level by day 25, as reflected in the histological examination of the kidneys on day 25. No signs of renal damage, including necrosis, degeneration, or inflammation, were observed, suggesting the absence of structural renal damage despite the transient biochemical changes. Therefore, the results highlight the potential of [Zn (LCX)(NCS)2] as a therapeutic candidate, demonstrating a favorable safety profile that warrants further investigation in preclinical studies. Future investigations should explore its impact across various cancer models while integrating advanced toxicity evaluations to thoroughly determine its therapeutic potential. Future aspects and limitations of the current studies Although the structure of the [Zn(LCX)(NCS)₂] complex is proposed based on FTIR, conductance, and NMR data, X-ray crystallography or mass spectrometry would provide more definitive evidence for the octahedral geometry of the complex. Due to limitations in this study, these techniques were not performed. Future research should consider incorporating these methods to confirm the exact molecular geometry of the compound. While this study focused primarily on breast cancer cells, we believe the compound may also have potential effects on other cancer types. Given that the compound targets key molecular pathways involved in cancer cell growth, it is likely that it could also impact other cancers, such as lung, colon, and prostate cancers. Future studies should expand on this by testing the compound in additional breast cancer cell lines to better understand its broader therapeutic potential. While the upregulation of p53, Bax, Caspases, and PARP1 suggests the activation of apoptotic pathways, the mechanistic role of zinc coordination remains speculative. It is well-established that zinc-based complexes can induce oxidative stress through ROS generation, which could contribute to apoptosis via the activation of pro-apoptotic proteins and mitochondrial dysfunction. Future studies should explore the role of ROS generation and mitochondrial membrane potential disruption as potential mechanisms driving apoptosis in MCF7 cells treated with the [Zn(LCX)(NCS)₂] complex. Due to limited funding and resources, we were unable to validate mRNA changes at the protein level using Western blot analysis, which may lead to discrepancies between gene expression and protein levels. Additionally, while we observed activation of the intrinsic apoptotic pathway, we did not investigate the extrinsic pathway, and thus, evidence for Bid cleavage or cytochrome c release was not assessed. Future studies should include Western blot analysis to validate the observed mRNA changes at the protein level. Furthermore, exploring the extrinsic apoptotic pathway, including Bid cleavage and cytochrome c release, would help confirm the involvement of both intrinsic and extrinsic pathways in the compound’s mechanism of action. For toxicity evaluation, future studies should include doses higher than the therapeutic dose (200 µg/kg/day) to thoroughly assess the toxicity and safety profile of the compound. To ensure the maximum tolerated dose and ensure a clear understanding of the compound’s safety margin. Conclusion In summary, the diisothiocyanatozinc(II) complex, [Zn(LCX)(NCS)₂], shows considerable cytotoxic effects on cancer cells, as evidenced by multiple bioassays. The brine shrimp lethality bioassay demonstrated a dose-dependent rise in mortality, suggesting its potential as a cytotoxic agent. In vivo studies further validated the compound’s efficacy, demonstrating significant inhibition of EAC cell proliferation and a notable decrease in ascites tumor burden, especially at elevated doses, which led to a reduction in cell growth. Furthermore, the compound significantly prolonged the survival time of tumor-bearing mice, highlighting its potential as a therapeutic agent. The compound exhibited a strong inhibitory effect on MCF-7 breast cancer cells, leading to apoptosis in a dose-dependent manner, accompanied by a notable upregulation of pro-apoptotic genes and a downregulation of anti-apoptotic genes. Additionally, the complex demonstrated a beneficial haematological profile, partially recovering RBC and haemoglobin levels in EAC-bearing mice while preserving stable parameters in normal mice, indicating low toxicity. Biochemical assessments revealed temporary changes in glucose and liver enzyme levels, followed by a return to baseline, supporting the compound’s promise as an effective anticancer agent with an acceptable safety profile. These findings strongly support the need for additional research into the [Zn(LCX)(NCS)₂] complex as a potential candidate for therapeutic applications in oncology. Supplementary Information Supplementary Material 1 Author contributions K.S., K.M.R., A.R., performed the experiment and drafted the manuscript; T.R.M., S.R., P.P., M.M.H., A.A., T.H.P., T.K., analyzed the data and generated figures; S.R.K., M.H.R., T.G.R., synthesized and characterized the compound; N.R., J.A.K., F.I. planned the project and edited the manuscript. Funding This work was supported by grants from the Dean of Science, Rajshahi University, Rajshahi-6205, Bangladesh (Grant No. 2002.5/52/RU./Science-35/2023–2024). Data availability The datasets generated and/or analysed during the current study are available in the BMRBdep repository [BMRB ID is 53373]. Code availability Not applicable. Declarations Ethics approval and consent to participate The study protocol received ethical approval from the Institutional Animal, Medical Ethics, Biosafety and Bio-Security Committee for Experimentations on Animal, Human, Microbes, and Living Natural Sources (No. 293(13)/320-IAMEBBC/IBSc), Institute of Biological Sciences (IBSc), University of Rajshahi, Bangladesh. Consent for publication All authors read the manuscript in the current version and provide their consent for publication. Competing interests The authors declare no competing interests. Footnotes Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Kazi Soha and K. M. Rashel have contributed equally to this work. Contributor Information M. Habibur Rahman, Email: mhr@ru.ac.bd. Farhadul Islam, Email: farhad_bio83@ru.ac.bd, Email: f.islam@griffith.edu.au. References Associated Data Supplementary Materials Supplementary Material 1 Data Availability Statement The datasets generated and/or analysed during the current study are available in the BMRBdep repository [BMRB ID is 53373]. Not applicable.